UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.581
NA - Nord America 4.053
EU - Europa 1.404
SA - Sud America 622
AF - Africa 62
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.733
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 5.721
US - Stati Uniti d'America 3.973
SG - Singapore 711
BR - Brasile 528
CN - Cina 527
IT - Italia 360
RU - Federazione Russa 273
VN - Vietnam 241
UA - Ucraina 180
DE - Germania 142
IE - Irlanda 121
TR - Turchia 121
KR - Corea 105
FI - Finlandia 63
SE - Svezia 63
GB - Regno Unito 48
CA - Canada 44
AR - Argentina 39
FR - Francia 32
IN - India 27
DK - Danimarca 26
ZA - Sudafrica 25
BD - Bangladesh 23
MX - Messico 23
NL - Olanda 23
ID - Indonesia 22
EC - Ecuador 21
JP - Giappone 17
AT - Austria 15
ES - Italia 12
PL - Polonia 12
IQ - Iraq 11
VE - Venezuela 11
CZ - Repubblica Ceca 10
PY - Paraguay 8
UZ - Uzbekistan 8
CO - Colombia 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
LT - Lituania 6
EU - Europa 5
MA - Marocco 5
PS - Palestinian Territory 5
TN - Tunisia 5
AU - Australia 4
GR - Grecia 4
HN - Honduras 4
PE - Perù 4
UG - Uganda 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
KE - Kenya 3
SN - Senegal 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
CG - Congo 2
CH - Svizzera 2
GE - Georgia 2
IR - Iran 2
KZ - Kazakistan 2
MW - Malawi 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
RO - Romania 2
SA - Arabia Saudita 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
GA - Gabon 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PH - Filippine 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TL - Timor Orientale 1
Totale 13.732
Salva come PNG Salva come JPEG
Città #
Hong Kong 5.715
Ann Arbor 778
Chandler 360
Princeton 344
Woodbridge 334
Jacksonville 263
Dallas 242
Ashburn 210
Singapore 201
Houston 174
Beijing 145
Dublin 118
Dong Ket 106
Izmir 106
Wilmington 102
Moscow 73
Nanjing 72
Andover 63
Munich 55
Los Angeles 50
São Paulo 50
Boardman 44
Pellezzano 44
Ho Chi Minh City 43
Naples 42
New York 35
The Dalles 31
Hanoi 29
Fairfield 27
Salerno 27
Redwood City 26
Changsha 24
Hebei 23
Norwalk 23
Shenyang 22
Turku 22
Columbus 20
Johannesburg 19
Washington 19
Rio de Janeiro 18
Santa Clara 18
Belo Horizonte 17
Jinan 17
Nanchang 17
Dearborn 16
Tokyo 16
Brooklyn 15
Montreal 15
Denver 14
Jiaxing 14
Nuremberg 14
Council Bluffs 12
Seattle 12
Tianjin 12
Amsterdam 11
Brasília 11
Copenhagen 11
London 11
Phoenix 11
Warsaw 11
Atlanta 10
Chennai 10
Chicago 10
Curitiba 10
Fisciano 10
Guangzhou 10
Helsinki 10
Jinju 10
Milan 10
Nürnberg 10
Boston 9
Maletto 9
Mexico City 9
Ottawa 9
Pontecagnano 9
Stockholm 9
Cambridge 8
Haikou 8
Haiphong 8
Rome 8
San Diego 8
Seoul 8
Tashkent 8
Zhengzhou 8
Dhaka 7
Düsseldorf 7
Edmonton 7
Lappeenranta 7
Ribeirão Preto 7
Ankara 6
Biên Hòa 6
Falls Church 6
Guayaquil 6
Porto Alegre 6
Salvador 6
San Francisco 6
San Mango Piemonte 6
Sorocaba 6
Uberlândia 6
Baghdad 5
Totale 10.692
Salva come PNG Salva come JPEG
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 730
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 712
Non Alcoholic Fatty Liver: Epidemiology and Natural History 596
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 576
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 473
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 407
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 361
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 338
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 325
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 293
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 292
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 284
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 267
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 251
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 236
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 185
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 169
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 166
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 163
The diagnostic conundrum in non-alcoholic fatty liver disease 162
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 137
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 136
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 130
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 127
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 124
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 124
Coeliac disease and C virus-related chronic hepatitis: a non association 123
Pharmacotherapy of alcoholic liver disease in clinical practice 120
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 114
Alcoholic Liver Disease and Hepatitis C Chronic Infection 114
Epidemiology and Natural History of Alcoholic Liver Disease 111
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 110
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 108
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 103
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 103
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 103
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 102
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 101
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 100
Adiponectin in hepatology 98
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 97
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 96
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 94
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 92
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 92
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 92
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 91
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 89
Lung ultrasound for diagnosis of pneumonia in emergency department 86
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 85
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 85
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 84
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 83
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 83
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 82
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 81
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 79
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 77
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 76
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 76
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 76
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 76
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 75
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 75
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 74
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 74
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 72
Viral hepatitis: Milestones, unresolved issues, and future goals 72
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 71
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 70
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 70
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 70
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 70
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 68
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 68
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 68
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 67
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 67
Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study 64
Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182, (S1590865821002140), (10.1016/j.dld.2021.04.029)] 64
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 63
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 57
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 57
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 57
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 57
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 56
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 56
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 55
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 54
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 54
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 52
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 52
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 49
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 49
Nutrigenomics and nutrigenetics in metabolic-(Dysfunction) associated fatty liver disease: Novel insights and future perspectives 48
THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen 47
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 46
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 45
THU0289 PERSISTENCE OF CIRCULATING CRYOGLOBULINS AND RELATED SYMPTOMS AFTER HEPATITIS C VIRUS ERADICATION IN PATIENTS WITH MIXED CRYOGLOBULIN SYNDROME 43
THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort 42
Totale 13.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021436 0 0 0 0 58 38 65 13 39 12 81 130
2021/2022609 6 6 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/20267.386 695 2.891 2.923 522 355 0 0 0 0 0 0 0
Totale 14.000